Silo Awarded US Patent for PTSD Treatment, Prepares for SPC-15 Clinical Trial

 Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” Following receipt of the Notice of Allowance, Silo filed the final issue paperwork, paid the issue fees, and expects formal issuance of the patent in the next 90 days

https://www.globenewswire.com/news-release/2025/01/08/3006256/0/en/Silo-Pharma-Awarded-US-Patent-for-Groundbreaking-PTSD-Treatment-and-Prepares-for-SPC-15-Clinical-Trial.html